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 INTRODUCTION 
Anemia is one of the major public health problems in the 
developing world. More then 70% of pregnant women in South-East 
Asia region suffer from nutritional anemia.(1) 
Anemia is the direct cause of maternal death in 10-15% of cases 
but is an associated cause in many maternal deaths due to haemorrhage, 
sepsis and cardiac failure.(2) 
Anemia in pregnancy is associated with an adverse obstetric 
outcome in form of spontaneous abortions, preterm labor, low birth 
weight babies and intrauterine growth retardation.  
It is paradoxical but true that though the cause of pregnancy 
anemia is known and iron therapy is cheap, anemia continues to take a 
heavy toll of maternal lives in most developing countries.  
The World Health Organisation (WHO) defines anemia in 
pregnant  women as hemoglobin level below 11 g / dl.  
Iron deficiency is the most common hematinic deficiency in 
pregnancy, followed by folate deficiency.  
Prevention or early treatment of pregancy anemia is the best 
prophylaxis  against maternal mortality.  
1
 Supplementation with iron and folic acid during pregnancy is an 
effective method for preventing mortality and morbidity associated with 
anemia and improving the outcome of pregnancy.  
One of the primary aims of antenatal care is to prevent and treat 
anemia during pregnancy, since the safety of labour and the puerperal 
state, to say nothing of the future health, depend upon the state of the 
patient’s hemoglobin reserve 
Iron is an essential component of hemoglobin in blood. The 
pregnant women needs 1000 mg of iron all through her pregnancy to 
maintain iron balance.  
Traditional iron therapy which is based on either oral 
administration of iron or blood transfusion has many drawbacks. Now 
parenteral administration of new well tolerated iron preparations like 
iron sucrose which has been successfully used in treatment of anemia 
has revolutionised the treatment of anemia. (3)   
This study was done to find out the efficacy and safety of 
intravenous iron sucrose in treatment of iron deficiency anemia in 
second trimester of pregnancy. 
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 REVIEW OF LITERATURE 
 
HISTORICAL ASPECTS OF ANEMIA 
The work of Hedin and Wintrobe in assessing the volume of 
packed red calls by various types of hematocrit and  work of Keith and 
Garothy in estimating blood volume lead to accurate laboratory 
definition of the presence or absence of anemia. 
 Pierre Blaud in 1832, discovered that ferrous sulphate tablets 
were effective therapy for iron deficiency anemia.  
  In 1932, Wintrobe deviced the concept of red cell indices. 
 In 1992 Price quantitated the variation in red cell size seen in 
various types of anemia.   
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 Review of Literature 
• Bayoumeu F, Subiran - Buisset C, Baka NE, Legagneur 
H, Monnier - Barbarino P, Laxenaire MC -  France, 
2002 March   conducted a randomised control study in 50 
patients with hemoglobin 8 to 10g/dl and ferritin <50 
microg/L.  
In intravenous group, iron dose was calculated from the formula:  
weight before pregnancy (kg) x (120g/l - actual hemoglobin g/l).  Oral 
group received 240 mg of iron sulphate per day for 4 weeks. Treatment 
efficacy was assessed by measurement of hemoglobin and reticulocytes 
on days 8,15, 21 and 30 and at delivery and of ferritin on day 30 and at 
delivery.  
Results:- An increase in hemoglobin rising from 9.6±0.79 g/dl to 
11.11±1.3 g/dl on day 30 in IV group and from 9.7±0.5g/dl to to 11 
±1.25g/dl on day 30 in per oral  group. On day 30 and at delivery  
ferritin was higher in IV group. A mean higher birthwegiht of 250 g  
was noted in IV group (not significant). 
• Bencaiova G. Von Mandach U, Zimmermann R Zurich 
University Hospital, Switzerland 2009 Jun; 144(2) : 135-9. 
Epub 2009 Apr 29 have done a study to assess and compare 
the efficacy and safety of two or three doses of intravenous 
4
 iron sucrose with daily oral ferrous sulphate in the 
prophylaxis of iron deficiency anemia in pregnant women 
260 women between 21st and 24th week with singleton 
pregnancy were randomised into either the intravenous iron 
group or oral iron group. Of 130 women in IV iron group 
75 received 2 doses of 200mg iron sucrose and 55 received 
3 doses of 200mg iron sucrose.  
The first dose was administered between 21st and 24th weeks, 
second dose between 28th and 32nd week and third between 35th and 37th 
week. Women of oral group were given oral tablets of 80mg ferrous 
sulphate daily, beginning on day of study enrolment and stopping on 
day of delivery.   
Conclusion:- There was no significant difference in the haematological, 
maternal and fetal outcomes in the parenteral route of iron prophylaxis 
in pregnant women. 
• AI RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, 
Haberal A – Ankara Maternity Hospital, Turkey 2005 
December conducted a randomised controlled study to 
compare the efficacy of intravenous iron to oral iron in 
treatment of anemia in pregnancy. 90 women with 
hemoglobin between 8 and 10.5g/dL and ferrtin <13 
microg/L received either oral iron polymaltose complex 
5
 (300mg elemental iron per day) or IV iron sucrose Æ dose 
calculated as follows: 
Calculated: Weight before pregnancy (kg) x (110g/L – actual 
hemoglobin g/L) x 0.24 +500 mg 
Results:- The change in hemoglobin from baseline was significantly 
higher in intravenous group than oral group.  
Ferritin values were higher in IV iron group with no serious adverse 
reactions.  
• Perewusnyk G, Huch R, Huch A, Breymenn C – Zurich 
University, Switzerland , 2002 July.  
Parenteral iron therapy in obstetrics – 8 years experience with 
iron – sucrose complex.  
Results:- Fe- sucrose complex has become a major interest to prevent 
functional Fe deficiency. Good tolerance to this formulation is partly 
due to low allergenic effect, partly due to slow release  of elementary Fe 
from the complex, incorporation into bone marrow for erythropoiesis is 
faster.   
By using parenteral iron sucrose in cases of severe iron 
deficiency, anemia during pregnancy is treated efficiently and rate of 
blood transfusion could be reduced to below 1% of patients per year.  
6
 • Wali A, Mushtaq A, Nilofer J Pak Med assoc 2002 Sep 52 (9) did a 
prospective  comparative study – efficacy, safety and compliance of 
intravenous iron sucrose and intramuscular iron sorbitol in iron 
deficiency anemia of pregnancy.  
A total number of 60 pregnant women with gestation age 12-34 
weeks who had iron deficiency anemia. They were divided into 3 
groups. Group A (n=15) received intravenous iron sucrose according to 
recommended dose containing 500mg of iron sucrose for storage, in 
group B (n=20) iron sucrose was administered according to deficit 
calculated as per formula but 200mg of iron was given for storage. 
Group C received intramuscular iron sorbitol in dose used as practice.  
Conclusion:- Intravenous iron therapy is safe, convenient and more 
effective than intramuscular iron therapy in treatment of iron deficiency 
anemia during pregnancy and can replace blood transfusion in antenatal 
period.  
• A study was conducted by Divakar hospitals Bangalore 
A cohort of 96 women were recruited if their Hb <11g/dl, IV iron 
sucrose 200mg was given and their Hb estimated after 4 weeks of 
therapy.  
A rise of >2g/dl was seen in 17.2%. 
A mean rise of 1.31g/dl in 92%. 
7
 • Al Momen et al 1996 Nov conducted a prospective, open 
label controlled trial in 111 pregnant women with iron 
deficiency anemia, with Hb <9 g/dL and divided into 2 
groups. Intravenous iron sucrose was administered as an 
infusion of single 100mg dose in normal saline every 1 to 3 
days. Controls receive intramuscular iron dextran (100mg 
on alternate days) till the calculated dose was reached.  
Intravenous iron therapy resulted in higher levels of Hb, with time 
to achieve maximum Hb in shorter period compared with controls. No 
serious adverse effects were noted in iron sucrose group whereas 6% of 
patients could not tolerate intramuscular iron dextran, who were 
excluded from study.  30% patients in control group had disturbing 
gastrointestinal symptoms and 32% were non-compliant.  
• Lipincott William, Pakistan institute of Medical Science 
conducted a randomised controlled study in 80 patients 
with gestational age 12-36 weeks from antenatal clinic and 
20 patients after postpartum haemorrhage with anemia.  
Group A received intravenous  iron sucrose  
Group B received intramuscular iron sorbitol.  
 
 
8
 Conclusion:- IV iron sucrose is safe, convenient and more effective 
than intramuscular iron therapy in treatment of iron deficiency anemia 
during pregnancy. It can minimise blood transfusion in postnatal 
women. Increase in Hb was noted 1 week after iron sucrose 
administration. 
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 ANEMIA 
Definition  
Anemia is a reduction in RBC mass and hemoglobin content of 
blood due to diminished production or increased destruction or loss of 
RBC. This results in reduced oxygen carrying capacity of blood and 
inadequate oxygen supply to tissues.  
 
 
 
 
 
 
ERYTHROPOIESIS 
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 Erythropoiesis 
After birth red cells normally develop only in red bone marrow.  
Erythropoietic stem cell (>20 µm) 
 
Proerythroblast (15-20µm) 
 
Early normoblast (Basophil) (14-17µm) 
 
Intermediate normoblast (Polychromatophil (10-15µm) 
    (Hb appears) 
 
Late normoblast [Orthochromatic and non-dividing] (7-10µm) 
 
Reticulocyte (7.3 µm) 
 
Mature RBC (7.2µm) 
FACTORS REQUIRED FOR RBC FORMATION (4) 
1. Proteins  
2. Minerals – Iron, copper, zinc and cobalt.  
3. Vitamins – Vitamin B12, folic acid, riboflavin and Vitamin C 
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 4. Erythropoietin – Principal stimulus for red cell production in 
hypoxia.  
 
 
 
 
 
 
 
 
 
 
 IRON METABOLISM  
Body iron distribution 
    Iron content, mg  
    (female 60 kg)  
Hemoglobin    1700 
Myoglobin / enzymes   300 
Transferrin iron   3 
Iron stores    0 – 300 
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 Bilirubin (excreted) 
Macrophage
Degrading Hb Æ Free iron 
Tissues  
Ferritin  
  Hemosiderin  
  Heme  
  Enzymes  
 
Free iron  
      Red Cells 
Hb 
Plasma  
Transferrin - FE 
Blood loss 0.7 mg 
Fe in menses/day  
Fe++ absorbed 
(small intestine) 
Fe excreted 
0.6mg daily  
 
 
 
 
 
 
 
 
 
IRON CYCLE 
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The Iron Cycle  
ABSORPTION OF IRON 
Iron absorption mostly occurs in duodenum and proximal 
jejunum. Mostly dietary iron is in ferric form which is not easily 
absorbed. Iron has to be reduced to ferrous form to be transported across 
the intestinal epithelium. 
Iron Transport : Iron is transported by 2 stages  
a) Brush border 
b) Serosal surface 
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 Brushborder of mucosal cell has mobilferrin which binds to iron 
and causes it to enter mucosal cell. The mucosal cell has apoferritin 
which binds iron and iron may be stored in mucosal epithelial cell or 
may be transported to blood. The regulation of iron absoption is by 
equilibrium between ferrous iron in mucosal cell, circulating iron levels 
and stored form of iron in mucosal cell  
Mucosal Block   
The  gut has a mechanism to prevent entry of excess iron in body. 
Iron reaching inside mucosal cell is either transported to plasma or 
oxidised to ferric form and complexed with apoferritin to form ferritin. 
This ferritin is generally stored in mucosal cell and is lost when they are 
shed (life span of mucosal cell is 2-4 days). This is called “FERRITIN 
CURTAIN” 
Transferrin is the protein involved in iron transport. Each 
transferrin is capable of binding one atom of iron. The transferrin-
receptor – iron complex moves inside the cell by an endosome and iron 
is released and taken up by DMT-1 (divalent metal transporter), that 
carries iron through endosome membrane to be incorporated intro iron 
containing proteins or to be stored as ferritin.   
The reticuloendothelial system phagocytoses old red blood cells 
and hemoglobin is liberated. Heme is further converted to biliverdin and 
iron is released and incorporated into ferritin or transported back to 
plasma.  
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 Incorporation of 
iron in erythroblasts 
Mature red cells in 
circulation  
Plasma Fe3+ 
transferin  
Storage within 
macrophages as 
ferritin and 
hemosiderin
Phagocytosis of 
senile red cells by 
macrophages  
Iron 
absorption  
Fe3+ 
ferritin 
Intestinal 
cell 
Exfoliation 
of cell with 
loss of iron 
 Iron Metabolism  
 
 
 
 
 
 
 
 
Nutritional Iron Balance (5) 
The balance of iron in humans is tightly controlled and designed 
to conserve iron for reutilization there is no regulated excretory pathway 
for iron, and only mechanism by which iron is lost from the body are 
blood loss and loss of epithelial cells from the skin, gut and genito 
urinary tract. This margin between the amount of iron available for 
absorption and the requirement of iron, this accounts for the great 
prevalence of iron deficiency worldwide.  
The amount of iron required from the diet to replace losses 
averages 15% in women of child bearing age. An individual with iron 
deficiency can increase iron absorption to about 20% of iron present in 
meat containing diet, but only 5-10% of iron in vegetarian diet, because 
certain food stuffs that include phytates & phosphates reduce iron 
absorption by 50%  when ionizable iron salts are given together with 
food, the amount of iron absorbed is reduced, this is true with iron in 
16
 ferric state. In pregnancy, during the last two trimesters, daily iron 
requirement increase to 5 to 6mg. That is the reason why iron 
supplements are strongly recommended for pregnant women.  
 
IRON DEFICIENCY ANEMIA IN PREGNANCY 
Definition  
According to WHO, anemia in pregnancy is present when the 
hemoglobin concentration of peripheral blood is 11g/dl or less.  Anemia 
is responsible for 17% of maternal deaths in developing countries.  
PHYSIOLOGICAL ANEMIA OF PREGNANCY (6) 
Disproportionate increase in plasma volume, RBC volume and 
hemoglobin mass during pregnancy. In addition there is marked demand 
of extra iron during pregnancy.     
ICMR CATEGORIES OF ANEMIA 
Category Severity (Hb level in 
g/dl) 
Mild 10-10.9 
Moderate 7-10 
Severe <7 
Very severe <4 
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 IRON REQUIREMENT IN PREGNANCY  
Demands for iron in pregnancy come to a total of about 900mg 
(range 700 – 1400mg) of which about  
• 500 to 600mg goes to the uterus and its contents 
• Around 150 to 200 mg are lost in the average blood loss at 
delivery and a similar amount is expended in lactation.  
• In addition, there is an increased maternal hemoglobin 
mass which consumes about 500mg, but this iron is 
returned to the stores after delivery.(7) 
• On the credit side, there is an average saving of about 225mg 
as a result of ammenorrhoea throughout pregnancy. (7) 
• This leaves a likely iron deficit of 600 to 700mg. 
In terms of daily needs, this approximates  
4-6 mg/day – Second trimester 
6-8 mg/day – Third trimester 
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 Prevalence of iron deficiency anemia in pregnancy 
Exact data on prevalence of anemia in women is not available but 
a crude estimate is that 500 million women between 15 and 49 yrs of 
age worldwide are anemic.(8) 
  According to World Health Organization estimates, upto 56% of 
all women living in developing countries are anemic.(9) 
In India, National Family Health survey-2, shows that 54% of 
women in rural and 46% of women in urban areas are anemic.(10) 
Prevalence of anemia during pregnancy is much higher. It is 
estimated that 60 million pregnant women world wide are anemic. In 
developing countries, the prevalence of anemia in pregnant women 
varies between 50 and 90%. 
In a steering committee report from India, 13% women were 
reported to have hemoglobin <5g% and 34% had hemoglobin less then 
8gm%.(11) 
Nutritional anemia is a serious problem in pregnancy which 
affects 60-70% of pregnant women.  
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 CAUSES OF INCREASED PREVALENCE OF ANEMIA IN 
TROPICS  
1. Faulty dietetic habit – High phosphate and phytates decrease 
absorption  
2. Faulty absorption mechanism – Due to intestinal infestation  
3. Iron loss –  (i)  Excess blood loss during menstruation  
(ii)  Repeated pregnancies at short  intervals  
(iii)  Hook worm infestation  
 
 
 
 
 
 
 
 
 
 
 
 Hook worm Life Cycle  
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 DURING PREGNANCY  
1. Increased demand (13) 
2. Diminished intake  
3. Disturbed metabolism  
CLINICAL FEATURES  
Symptoms Signs 
• Lassitude  • Pallor , Koilonychia  
• Palpitation  • Glossitis and stomatitis  
• Dyspnoea  • Tachycardia  
• Giddiness • Systolic heart murmur 
• Pica  • Oedema (due to hypoproteinemia) 
Koilonychia 
 
 
 
 
 
 
 
 
21
 Angular Stomatitis 
 
    
 
  
 
Eyes – Pallor  
 
 
 
 
 
 
Smooth Bald Tongue  
 
 
 
 
 STAGES OF IRON DEFICIENCY 
 
 Normal
Negative 
Iron 
balance 
Iron deficient 
erythropoiesis
Iron 
deficiency 
anemia 
1. Marrow iron 
stores  
1-3+ 0-1+ 0 0 
2. Serum ferritin 
(μg/L) 50-200 <20 <15 <15 
3. TIBC (μg/dl) 300-
360 
>360 >380 >400 
4. Serum iron 
(μg/dl) 50-150 NL <50 <30 
5. Saturation (%) 30-50 NL <20 <10 
6. Marrow 
Sideroblasts  
40-60 NL <10 <10 
7. RBC 
protoporphyrin 
(μg/dl) 
30-50 NL >100 >200 
8. RBC 
morphology  
NL NL NL 
Microcytic 
hypochromic
* NL  - Normal Limits  
 
 
Storage Iron  
 
Transport Iron 
 
Erythron Iron 
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 COMPLICATIONS OF SEVERE ANEMIA 
During 
pregnancy 
Labour Puerperium Fetal effects 
Pre-eclampsia  Uterine 
inertia  
Pureperal sepsis  Low birth 
weight  
Intercurrent 
infection  
Postpartum 
haemorrhage  
Subinvolution  Intrauterine 
death 
(anoxemia)  
Heart failure at 
30-32 weeks of 
gestation  
Cardiac 
failure  
Puerperal venous 
thrombosis  
 
Preterm labour  Shock  Pulmonary 
embolism  
 
 
Postpartum Haemorrhage 
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 Cardiac failure 
 
 
 
 
 
 
 
 
Puerperal venous thrombosis 
 
 
 
 
 
 
 
 Pulmonary embolism 
 MANAGEMENT OF IRON DEFICIENCY ANEMIA  
Investigations  
I.  To know degree of anemia  
Determination of hemoglobin concentration:- 
a) Tallquist method  
b) Sahli’s acid hematin method  
c) Alkali – hematin method  
d) Cynmethhemoglobin method – most accurate  
II.  To assess type of anemia  
a) Peripheral smear:- Single best investigation   
The differential RBC morphology like micro or macrocytosis, 
hypo or normochromia, anisocytosis, poikilocytosis, howel jolly bodies, 
heinz bodies, presence of target cells and schizocytes serve as important 
clues to the aetiology.  
It also provides information about white blood cells (WBC), 
differential count and morphology, platelet count, presence of parasites 
like malaria and kala-azar, and toxic granules in case of chronic 
infections. 
The reticuloyte count requires supravital staining of the peripheral 
smear.  
24 
  
  
 
 
 Hematological indices (15) 
a. MCV (Mean corpuscular volume) 
          Packed cell volume % 
MCV = ------------------------------------- x 10 
               RBC count in millions/cu.mm  
 
Normal range : 80-95 fl 
b. MCH (Mean corpuscular hemoglobin)  
 
                 Hemoglobin g/dl 
c. MCH (Picograms) = ---------------------------------------- x 10 
        RBC count in millions/cu.mm  
Normal range : 27-32 pg 
d. MCHC (Mean Corpuscular hemoglobin concentration) 
                      Hemoglobin g/dl 
MCHC (g/dl) = -------------------------------- x 100 
                   Packed cell volume  
 
Normal range : 34 – 37 g/dl  
III.  Other Blood values  
1. Serum iron: 50-150 µg/L 
2. TIBC (Total Iron Binding Capacity) 
Normal 325-400 µg/dl 
Increased in iron deficiency anemia  
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 3. Transferrin saturation  
 Serum iron  
---------------  x100 
     TIBC  
 
Normal : 20-50% 
Decreased in iron deficiency anemia  
4. Serum ferritin :- Normal value  50 – 200 μg/ l 
- Most sensitive and specific test for iron deficiency anemia  
- It correlates with body iron stores 
5. Soluble transferrin receptor assay (TFR). (16) 
o Indicates cellular iron status  
o Increased in iron deficiency anemia.  
6. Free erythrocyte protoporphyrin:- Increased in iron deficiency 
anemia. 
7. Red cell distribution width – It is the degree of variation of red 
cells size.  
It is increased in iron deficiency anemia and helps in 
distinguishing from beta-thalassemia, where red cell distribution width 
is normal.  
IV.  Examination of stool: To detect helminthic infection (especially 
hookworm) 
26
 V.   Examination of urine – for protein, sugar and pus cells.  
VI.   Bone marrow aspiration and examination  
INDICATION 
a) Cases not responding to therapy  
b) To diagnose hypoplastic anemia  
c) To diagnose kala-azar 
TREATMENT OF IRON DEFICIENCY ANAEMIA 
PROPHYLACTIC SUPPLEMENTATION 
An additional 500-600mg iron is required in pregnancy at a rate 
of 4-6 mg/day increasing upto 8mg/day in later stages of pregnancy. The 
average Indian diet seldom contains more than 15mg of iron per day, of 
which only a fraction (about 10%) is available for absorption.  
So there is a definite role of prophylactic supplementation in 
pregnant women in developing countries. 
Natural foods like liver, meat, eggs, peas, green leafy vegetables, 
sprouts, jaggery and certain dried fruits are sources of iron.  
• WHO recommendation based on the prevalence of anemia is 60 
mg elemental iron with 400 microgram of folic acid for 6 months, 
where prevalence of anemia is <40% and this dose to be 
27
 supplemented for another 3 months postpartum in areas where the 
prevalence >40%. (17) 
• The National Nutritional Anaemia control programme of India 
recommends 100mg elemental iron and 500 microgram of folic 
acid for prophylactic supplementation for a minimum of 100days 
starting in second trimester. (18) 
• Double this dose for the treatment of anemia that is 200mg 
elemental iron and 1000 microgram of folic acid. These cases 
need to continue the iron supplementation in postpartum period 
for 3-6months to replenish stores 
28 
 Treatment 
Oral therapy 
There must be atleast 10 weeks for delivery to obtain satisfactory 
result with oral iron.  
Iron is best absorbed in the ferrous form  
Ferrous sulphate is cheapest of these and is suitable for  most 
patients. 
Other expensive forms like ferrous fumarate, gluconate and 
succinate may produce less epigastric discomfort. 
Iron preparations should preferably be taken on an empty stomach 
to prevent dietary factors from interfering with its absorption. 
Recently two newer preparations namely carbonyl iron and iron 
polymaltose complex have been shown to be effective with lesser 
gastrointestinal side effects. (19) 
Treatment should be continued till the blood picture becomes 
normal, thereafter a maintenance dose is to be continued for atleast 100 
days following delivery to replenish the iron stores. 
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 Drawbacks 
1. Intolerance – Evidenced by epigastric pain, nausea, vomiting and 
diarrhoea or constipation. 
2. Unpredictable absorption rate – Antacids, oxalates and phospates 
will reduce absorption. 
3. With the therapeutic dose, the serum iron may be restored but 
there is difficulty in replenishing the iron stores. 
Rate of improvement 
The improvement should be evident within three weeks of 
therapy. 
Hemoglobin concentration is expected to rise at the rate of 
0.7gm/100ml per week. 
Contraindications of oral therapy 
1) Intolerance to oral iron. 
2) Severe anemia in advanced pregnancy 
PARENTERAL THERAPY 
 Indications:- 1. Intolerance to oral iron 
2. Patient is not co-operative to take oral iron 
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 (A) Intravenous route 
(i) Total dose infusion:-  The deficit of iron is first calculated and 
total amount of iron required to correct the deficit is administered by a 
single sitting intravenous infusion. The compound used is iron dextran. 
1 ml of which contains 50 mg elemental iron.  
Advantage:-  It eliminates repeated and painful intramuscular 
injections. 
Estimation  of the total Iron requirement (20) 
0.3 x W (100-Hb%) 
W → patient’s weight in pounds;  
Hb – hemoglobin 
Additional 50% is to be added for replenishment of the body iron 
store. 
B)  Intra muscular therapy:- The compounds used are  
(i)  Iron dextran (Imferon) 
(ii)  Iron – sorbitol – citric acid complex (Jectofer) 
Both preparations contain 50 mg elemental iron in one milli litre. 
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 Oral iron should be suspended atleast 24 hours prior to therapy to 
avoid reaction 
Both compounds require a test dose to be given 
The injections are given into upper outer quadrant of the buttock 
Drawbacks  
1) Injections are painful 
2) Chance of abcess formation and discolouration of skin over the 
injection site 
3) Reactions - Pyrexia, Lymphadenopathy, headache, nausea, 
vomiting and allergic reactions are infrequently met with. 
Rate of improvement : The expected rise in hemoglobin concentration 
is 0.7 gm / 100ml per week The rate of response to iron therapy is the 
same whether given orally or parenterally  
Newer injectable iron preparations now available are iron polymaltose 
for intramuscular and intra venous use and sodium ferric gluconate for 
intravenous use. (21)    
Place of Blood Transfusion 
Indications 
1) To correct anemia due to blood loss and  
 to combat postpartum hemorrhage 
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 2) Patients with severe anemia seen in later months of pregnancy 
3) Refractory anemia – not responding to either oral or parenteral therapy    
4) Associated infection 
Advantages  
1) Increases oxygen carrying capacity of the blood  
2) Stimulates erythropoiesis 
3) Supplies the natural constituents of blood like proteins, 
antibodies, etc 
4) Improvement is expected after 3 days 
Draw backs  
1) Premature labour  
2) Increased chance of cardiac failure with pulmonary edema 
because of over loading of heart 
3) Transfusion reactions 
Erythropoietin 
 Recently this has been tried in resistant cases of anemia during 
pregnancy and anemia associated with end stage renal disease.  
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 - It acts by stimulating erythropoiesis and therefore may be an 
alternative to blood transfusion 
- Recombinant human erythropoietin (rHu Epo) given at a dose of 
150 IU / kg subcutaneously thrice a week.(22)   
- Administration of rHuEpo seems to be safe for the fetus since it 
does not cross the placental barrier due to its high molecular 
weight  
- Adequate iron stores need to be present for the treatment to be 
effective 
Side Effects  
 Hypertension and thrombosis in mother, more often in women 
with end stage renal disease.   
IRON SUCORSE 
 
 
 
• It is a sterile complex of polynuclear iron (III) hydroxide for 
intravenous use with molecular weight of approximately 60,000 
daltons.  
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 • Each ml contains 20mg elemental iron as iron sucrose in water for 
injection.  
• The drug product contains 30% sucrose and pH 10.5-11.1 
• It has no preservatives and the osmolality 1.250 mOsmoL/L. 
 
MECHANISM OF ACTION  
After iv injection, iron sucrose mix with plasma, then enter 
reticuloendothelial system directly from intravascular fluid 
compartment. Resident phagocytes of liver, spleen and bone marrow 
remove iron agents from circulatory plasma. Within phagocytes, iron is 
released from the iron sucrose compound into iron pool. Iron is either 
incorporated by ferritin into intracellular iron stores or released from the 
cell to be taken up by the extracellular iron binding protein transferrin. 
Iron-transferrin supplies iron for hemoglobin synthesis and maturation 
of red blood cells.   
PHARMACOKINETICS  
 Iron component exhibits first order kinetics  
 Elimination t ½ : 6 hrs  
 Total clearance 1.2 l/hr 
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        Non-steadyÆ 10 litres  
 Apparent volume of distribution   
       Steady state Æ 7.9 litres  
 Iron sucrose mainly distributes in blood and to some extent in 
extra vascular fluid. 
Elimination  
  Sucrose component and some iron is eliminated by urinary 
excretion.  
Side effects  
• Hypotension  
• Cramps (Leg cramps) 
• Nausea  
• Headache  
• Vomiting  
• Diarrhoea  
METHOD OF ADMINISTRATION  
1. SLOW IV INJECTION  
100mg to be administered undiluted over a period of 2-5 minutes.   
state 
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 2. IV INFUSION  
100mg to be diluted with 100ml of normal saline immediately 
prior to infusion and infused over a period of at least 15 minutes.  
Maximum 100-200mg given as single dose repeated upto 3 times 
a week on alternate days.  
Storage: stored at 25°C 
Excursions permitted 15-30°C  
 
SALIENT FEATURES OF IRON SUCROSE  
1. It is safe and effective in pregnancy anemia.  
2. It has convenient dosage and administration.  
3. It is a stable high molecular complex which does not cause 
transferrin saturation.  
4. It does not cause oxidative cell toxicity due to free iron 
generation.  
5. It has a safety profile established worldwide.  
6. It is safe for patients intolerant to other IV iron preparations.  
7. No parenchymal damage.  
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 AIM OF STUDY 
AIM OF STUDY :  
1. To determine  efficacy of iron sucrose in treating iron 
 deficiency anemia in antenatal patients  
2. To determine safety of iron sucrose in treatment of iron 
 deficiency anemia in antenatal patients 
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 MATERIALS AND METHODS 
 STUDY PLACE   :  Institute of Obstetrics and Gynaecology 
 STUDY PERIOD : 2009 to 2010 
 STUDY DESIGN : Prospective Study 
 50 antenatal patients in second trimester with hemoglobin > 6 
grams %  and < 11 grams % were selected.  
 
INCLUSION CRITERIA 
a) Gestational age 13 to 28 weeks  
b) Hemoglobin > 6 gm % to < 11 gm %  
EXCLUSION CRITERIA 
1) Patients in first and third trimester of pregnancy.  
2) Bleeding disorders.  
3) Patients who had known allergy to parenteral iron. 
METHOD  
Iron sucrose was given as an intravenous infusion.  
No test dose required 
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  200mg iron sucrose was diluted with 100 ml of normal saline 
immediately prior to infusion and is to be infused over a period of 
atleast 30 minutes to 1 hour. The same dose repeated after 2 days.  
 We did not calculate the optimal dose of iron sucrose required by 
each women based on her pre – treatment hemoglobin; we studied the 
response to a uniform dose over a range of pre – treatment hemoglobin 
values.  
 Hemoglobin, packed cell volume were analysed by automatic cell 
counter. Serum iron, total iron binding capacity was calculated using 
semi auto analyser.  
An informed consent obtained from patient and a detailed history 
taken. 
OBSERVATION 
 The following investigations were done before starting therapy.  
1. Hemoglobin  
2. Packed cell volume  
3. Peripheral smear 
4. Serum iron  
5. Total iron binding capacity  
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 6. Iron saturation  
7. Serum ferritin 
During therapy the following were monitored  
1. Vitals  - Pulse rate, Blood Pressure,  Temperature.  
2. Anaphylactic reactions  
3. Adverse effects  - Nausea, Vomiting, Chills & Rigors,  
     Abdominal Pain, Headache etc.   
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 RESULTS 
I . AGE DISTRIBUTION 
Age group No. of Mothers % 
18 – 20 Yrs 11 22.0% 
21 – 25 Yrs 18 36.0% 
26 – 30 Yrs 17 34.0% 
31 – 35 Yrs 4 8.0% 
Total 50 100 
 
Among the fifty patients 22% (11/50) were in the age group 18 – 20 yrs.  
*  36% (18/50) were in age group 21 – 25 yrs.  
* 34% (17/50) were in age group 26 – 30 yrs  
* 8% (4/50) were in age group 31 – 35 yrs.  
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 II. SOCIOECONOMIC STATUS  
Socio Economic  
Status 
Number of  
Mothers 
% 
I - - 
II - - 
III - - 
IV 10 20 
V 40 80 
Total 50 100 
 
Among the fifty patients, 20% (10/50) are in class IV Socio – 
economic status.  80% (40/50) are in Class V socio economic status.  
Number of Mothers
0%
20%
80%
I
II
III
IV
V
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 III. BOOKING STATUS  
Booking Status No. of 
Mothers 
% 
Booked 38 76% 
Un booked 12 24% 
Total 50 100 
 
Among the fifty patients, 76% (38/50) were booked and 24% 
(12/50) were un-booked.  
No. of Mothers
76%
24%
Booked 
Un booked 
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 IV. OBSTETRIC CODE  
Obstetric Code Number of 
Mothers % 
P1 L1 22 44% 
P2 L2 20 40% 
P3 L2 4 8% 
P3 L3 3 6% 
P4 L2 1 2% 
Total 50 100% 
Among the fifty patients 
*  44% (22/50) were P1 L1 
* 40% (20/50) were P2 L2 
* 8% (4/50) were P3 L2 
* 6% (3/50) were P3 L3 
* 2% (1/50) were P4 L2 
 
 
 
 
 
Number of Mothers
44%
40%
8%
6% 2%
P1 L1
P2 L2
P3 L2
P3 L3
P4 L2
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 V. Mode of Delivery  
Mode of Delivery No. of Mothers % 
Emergency LSCS  8 16.0 
Emergency repeat LSCS  2 4.0 
Emergency repeat LSCS with 
sterilization)  
6 12.0 
Labour Natural  4 8.0 
Labour natural with LP  4 8.0 
Labour natural with episiotomy 24 48.0 
Total    
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 VI. Hemoglobin 
 Mean (g/dl) SD 
Repeated 
Measures 
Anova F Test 
Before iron sucrose  7.70 0.76  
F = 8694.2 
P = 0.001 
After Month  10.32 0.74 
At delivery  11.43 0.89 
 
The change in hemoglobin level was significant  
Before iron sucrose administration - Mean hemoglobin was 
7.70mg / dl  
  1 month after iron sucrose administration, mean hemoglobin was  
10.32 g / dl mean  
 At delivery, hemoglobin 11.43 g / dl.  
 p value 0.001 which was significant.  
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 Multiple comparison using Bonferroni t-test 
 
I 
J 
Mean 
Difference 
(I-J) 
Significance
95% Confidence 
Interval for 
Difference(a) 
Lower            
After 
Before 
iron 
sucrose 
 
After I 
month -2.618(*) .001 -2.803 -2.433 
At 
delivery -3.732(*) .001 -3.938 -3.526 
After I 
month 
 
Before 2.618(*) .001 2.433 2.803 
At 
delivery -1.114(*) .001 -1.256 -.972 
At 
delivery 
 
Before 3.732(*) .001 3.526 3.938 
After I 
month 1.114(*) .001 .972 1.256 
Based on estimated marginal means 
*  The mean difference is significant at the .05 level. 
Hemoglobin 
Hb 
Mean 
difference 
(g/dl) 
Std. 
Deviatio
n 
Paired 
t - test 
Significanc
e (2 – 
tailed) 
Pair 1 After 1 month – 
Before  
2.618 0.52 35.095 0.001 
Pair 2 – At delivery Before 3.732 0.58 44.950 0.001 
Pair 3 At delivery – After  1.114 0.40 19.470 0.001 
 
48 
 HAEMOGLOBIN
0
2
4
6
8
10
12
14
16
m
ea
n 
H
b
Before After 1month At delivery  
 
 
 
Haemoglobin  
0 
2 
4 
6 
8 
10 
12 
14 
Before iron 
sucrose 
After Month At delivery 
Mean (g/dl)
 VII. SERUM FERITIN  
 Mean SD 
Repeated 
meaures ANOVA 
F-test 
Before iron sucrose 21.40 7.00 
F=1816.1 
P=0.001 
After 1 month 85.03 15.96 
At delivery 177.29 27.65 
 
Mean Serum ferritin  before iron sucrose administration was 
21.40 μg /l  
After 1 month of iron sucrose administration it was 85.03 μg/l  
At delivery serum ferritin was 177.29 μg/l  
P value 0.001 & was significant  
 
SR. FERRITIN Mean difference
Std. 
Deviation 
Paired  
t-test 
Sig.  
(2-tailed)
Pair 1 After 1 month 
– Before 63.63 0.52 34.789 .001 
Pair 2 At delivery - 
Before 92.26 0.58 45.530 .001 
Pair 3 At delivery - 
After 1 month 92.26 0.40 41.671 .001 
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 Multiple comparison using Bonferroni t-test 
I J 
Mean 
Difference 
(I-J) 
Significance
95% Confidence 
Interval for 
Difference(a) 
Lower              
After 
Before 
iron 
sucrose 
  
After I 
month -63.630(*) .001 -68.042 -59.218 
At 
delivery -155.890(*) .001 -164.378 -147.402
After I 
month 
  
Before 63.630(*) .001 59.218 68.042 
At 
delivery -92.260(*) .001 -97.748 -86.772 
At 
delivery 
  
Before 155.890(*) .001 147.402 164.378 
After I 
month 92.260(*) .001 86.772 97.748 
*  The mean difference is significant at the .05 level. 
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VIII. PCV – PACKED CELL VOLUME  
 Mean 
Std. 
Deviation Paired t-test 
 Before iron sucrose 24.08 2.54 t=25.13 
P=0.001***   After one month 31.91 2.63 
* significant at p<0.05  ** significant at p<0.01   *** significant at 
p<0.001  
- Mean PCV before administration of iron sucrose 24.08  
- After one month mean PCV 31.91  
 P value 0.001 & was significant  
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 IX. SERUM IRON  
 Mean Std. Deviation Paired t-test 
Before iron sucrose
 
60.82 6.140 t=34.78 
P=0.001*** 
After one month 94.64 9.253 
significant at p<0.05  ** significant at p<0.01   *** significant at 
p<0.001   
Mean serum iron before administration of iron sucrose 60.82 μg/dl.  
1 Month after iron sucrose administration 94.64 μg/dl  
P value 0.001 & was significant  
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 X. TOTAL IRON BINDING CAPACITY (TIBC)  
 Mean Std. Deviation Paired t-test 
 Before iron sucrose 375.82 60.835 t=11.96 
P=0.001***  After one month 256.32 37.507 
 
* significant at p<0.05  ** significant at p<0.01   *** significant at 
p<0.001 
Mean TIBC before iron sucrose administration was 375.82.  
Mean TIBC 1 month after iron sucrose administration was 256. 32.   
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 XI. PERCENTAGE SATURATION OF IRON  
 Mean Std. Deviation Paired t-test 
 Before iron sucrose 16.189 3.5137 t=26.46 
P=0.001***   After one month 37.875 7.8960 
* significant at p<0.05  ** significant at p<0.01   *** significant at 
p<0.001   
• Mean percentage saturation of iron before iron sucrose 
administration was 16.189%. 
• Mean percentage saturation of iron 1 month after iron sucrose 
administration was 37.875%.  
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XII. SIDE EFFECTS  
Side Effects No. of mothers % 
Nil 45 90.0 
Chills & rigors 2 4.0 
Headache 1 2.0 
Nausea 1 2.0 
Thrombophlebitis 1 2.0 
Total 50 100.0
 
Of the fifty patients 90% (45/50) had no side effects.  
- 4% (2/50) had chills & rigors  
- 2% (1/50) had headache  
- 2% (1/50) had nausea  
- 2% (1/50) had thrombophlebitis  
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 DISCUSSION 
In this study, 50 antenatal patients with iron deficiency anemia 
were selected according to the inclusion and exclusion criteria stated.  
200 mg iron sucrose was given intravenously 2 doses 2 days apart 
and  was followed up after  1 month interval & again at delivery.  
• In our study, among the fifty patients 36% (18/50) were in  
age group 21 – 25 yrs.  
22% (11/50) were in age group 18 – 20 yrs.  
34% (17/50) were in age group 26 – 30 yrs  
8% (4/50) were in age group 31 – 35. 
• In our study, among the fifty patients  
20% (10/50) were in class IV socio economic status  
80% (40/50) were in class V socio economic status  
• Among the fifty patients in our study, 76% (38/50) were booked  
24%  (12/50) were unbooked.     
• Obstetric code among the fifty patients, was  
* P1 L1  44%  (22/50)  
* P2 L2  40%  (20/50)  
* P3 L3   6% (3/50) 
* P4 L2   2% (1/50)  
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 COMPARISON OF THE OUTCOME OF THE PARAMETERS 
1. CHANGE IN HEMOGLOBIN:-  
 In our study of 50 antenatal patients, mean hemoglobin before 
starting treatment was 7.70 g/dl.  
• 1 Month after iron sucrose administration mean hemoglobin was           
10.32 g /dl.  
• At delivery, mean hemoglobin was 11.43 g/dl.  
The average raise is 3.73 g/dl with a p value < 0.05 which is 
statistically significant. 
Change in Hemoglobin  
 
Study Rise  in hemoglobin 
Bayoumeu et al  1.6 + 0.79 g/ dl  
AI RA, Unlubilgin et al  2 g/dl  
Divakar  0.9 – 2 g/dl  
Wali A et al  1.9 – 2.8 g/dl  
Krafft  A et al  1.1 – 2  g/dl  
Bhandal R Russel et al  3.7 g / dl  
A. Dede et al  4.3 + 0.6 g/dl  
This study  3.73 g/dl  
 This study is similar to Bhandal R Russel et al study.  
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 2. CHANGE IN FERRITIN  
• In our study of 50 antenatal patients, mean serum ferritin  
was 85.03 μg/l.  
• 1 Month after iron sucrose administration, mean serum ferritin 
was 85.03 μg/l.   
• At delivery, mean serum ferritin was 177 – 20 μg/l.  
The average rise is 155.89 μg/l. with p value < 0.05 is statistically 
significant.  
Change in Ferritin:         
 
Study  Rise in serum ferritin 
Bayoumeu et al   Ferritin was higher after iron 
sucrose  
AI RA, unlubilgin et al   Ferritin values were higher in 
intravenous iron sucrose group  
Our study   Mean rise in serum ferritin  
155.89 µg/L  
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 3. CHANGE IN PACKED CELL VOLUME 
• Mean packed cell volume before starting treatment 24.08.  
• 1 Month after iron sucrose administration mean packed cell 
volume is 31.91.   
The average rise in mean PCV is 7.83 with p value < 0.05 and is 
statistically significant.  
4. CHANGE IN SERUM IRON  
Mean serum iron before iron sucrose administration is 60.82 
μg/dl.  
Mean serum iron 1 month after iron sucrose administration is 
94.64 μg/dl.  
The average rise in mean serum iron is 33.82 μg/dl, with p value 
< 0.05 & is statistically significant.  
Change in serum iron: 
Study Rise in serum iron 
A. Dede, D.uygut et al  43.4 µg/dl  
This study  33.82 µg/dl  
  Our study correlated with A.Dede et al and all other studies and 
showed rise in serum iron after intravenous iron sucrose.  
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 5. CHANGE IN TOTAL IRON BINDING (TIBC) CAPACITY 
Mean TIBC before iron sucrose administration is 375.82.  
Mean TIBC 1 month after iron sucrose administration is 256.32.  
The average decrease in mean TIBC is 119.5 with p value < 0.05 
and is statistically significant.  
Change in TIBC: 
Study  Decrease in TIBC 
A Dede et al  123.8  
This study  119.5 
 
6. CHANGE IN PERCENTAGE SATURATION OF IRON 
Mean percentage saturation of iron before iron sucrose 
administration 
16.189%.  
Mean percentage saturation of iron 1 month after iron sucrose 
administration is 37.875%.  
The average rise in mean percentage saturation of iron is 21.686% 
with p value < 0.05 and is satistically significant.  
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 7. SIDE EFFECTS 
 90%  (45/50) had no side effects.  
 4% (2/50) had chills & rigors  
 2% (1/50) had headache  
 2% (1/50) had nausea  
 2% (1/50) had thrombophalebitis.  
Adverse reactions:  
Study Incidence of adverse reactions 
N Bhandal, R Russel et al  Nil 
Giannoulis et al  0.002%  
Khurshid et al  Nil  
Our study 10%  
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 SUMMARY 
In our study of 50 antenatal patients with iron deficiency anemia, 
were selected according to inclusion & exclusion criteria mentioned.  
METHOD   
200 mg of iron sucrose was given intravenously 2 doses 2 days  
apart, & followed up 1 month after administration of iron sucrose and at 
delivery.  
The following parameters were assessed 
1. Hb in g/dl  
2. PCV  
3. Serum ferritin in μg/l  
4. Serum iron in μg/dl  
5. Total iron binding capacity  
6. Percentage saturation of iron.  
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 THE RESULTS OF THE STUDY ARE AS FOLLOWS 
1. Majority of patients around 36%, were in age group 21 – 25 yrs.   
2. 80% of patients were in class V socio economic status.  
3. 76% patients were booked  
4. Majority of patients were multiparous  
5. Average rise in hemoglobin after treatment was 3.73 g/dl with p 
value < 0.05, statistically significant.  
6. Average rise in serum ferritin after treatment was 155.89 μg/l 
with p value < 0.05, statistically significant.  
7. Average rise in packed cell volume after treatment was 7.83 with 
p value < 0.05, statistically significant.  
8. Average rise in serum iron after treatment  was 33.82 μg/ l with p 
value < 0.05, statistically significant.  
9. Average rise in total iron binding capacity after treatment was 
119.5 with p value < 0.05, statistically significant.  
10. Average rise in percentage saturation of iron after treatment was 
21.686% with p value < 0.05, statistically significant.  
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 11. Side effect profile were very minimal with 90% patients (45/50) 
had no side effects  
2 patients had chills & rigors   
 1 patients had headache  
 1 patients had nausea  
 1 patients had thrombophlebitis  
 No anaphylactic reactions occurred.  
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 CONCLUSION 
1. Intravenous iron sucrose has become a major interest  to prevent 
functional iron deficiency.  
2. Iron sucrose has been found to be effective in improving 
hemoglobin, hematocrit, serum iron & ferritin values significantly 
in antenatal women with iron deficiency anemia 
3. There is good tolerance to this formulation partly due to low 
allergenic effect and partly due to slow release of elementary iron 
from the complex. 
4. By using intravenous iron sucrose to treat iron deficiency anemia 
in antenatal patients, the rate of blood transfusions could be 
reduced.  
To conclude intravenous iron sucrose is safe, convenient and 
more effective therapy for treatment of iron deficiency anemia in 
antenatal patients requiring shorter period to achieve maximum 
hemoglobin concentration. It has convenient dosage and administration. 
It can be used to replace blood transfusion in antenatal period.   
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 PROFORMA 
Study of efficacy of intravenous iron sucrose  in treating anemia in 
antenatal women 
Name Occupation  
Age Address  
IP Number Phone Number  
Income Socio-Economic Class  
Obstetric Score   
Para   
Live   
Abortions   
Presenting Complaints Yes No 
H/o. easy fatigablility   
H/o breathlessness   
H/o swelling of legs   
H/o puffiness of face   
H/o haemetemesis / malena   
H/o passing worms in stool   
History suggestive of iron 
intolerance  
  
Past H/o 
- H/o Diabetes mellitus, hypertension bronchial asthma, 
epilepsy, tuberculosis.  
- H/o blood transfusion  
Menstrual H/o   
Age at menarche:   
Cycles Regular Irregular 
Flow  a) Moderate Excess 
 b) Lasting for Days 
Marital H/o   
Married Since :    
Obstetric H/o   
 
 
 
Details of previous pregnancy / pregnancies: 
I. Any antenatal 
complication 
1 2 3 4 
1) APH 
2) PIH 
3) GDM  
4) Others 
    
II. Outcome of pregnancy      
1. Spontaneous abortion 
2. Induced abortion 
3. Pre-term delivery 
4. Term delivery 
a) Normal vaginal  
b) Vaginal instrumental  
c) LSCS 
 
 
 
 
 
 
 
 
 
 
  
III Place of delivery:      
Hospital / Nursing Home     
SC/ PHC / CHC      
IV Any Complication during  
Labour, delivery,  puerperium  
a) No 
b) PPH 
c) Sepsis 
 
 
 
 
 
 
 
 
 
 
  
V) Baby’s Status at birth 
Healthy live birth  
    
  Birth weight  
Low birth weight 
Asphyxiated 
Still birth 
Congenitally malformed 
Large birth weight  
Present Pregnancy Yes No 
H/o antepartum haemorrhage 
H/o heart disease 
H/o diabetes 
H/o PIH 
H/o GDM 
  
General Examination Yes No 
Features of anemia 
1. Pallor  
2. Glossitis 
3. Facial puffiness 
4. Koilonychia 
  
Vital Signs   
Temperature  
Pulse rate  
Blood Pressure 
CVS 
RS 
  
  
INVESTIGATIONS  
1. Urine  :  Albumin  
  Sugar  
  Deposits  
2. Blood   Sugar  
  Urea  
3. Serum : Creatinine  
4. Hemoglobin 
5. Packed cell volume (Hematocrit) 
6. Peripheral Smear  
7. Serum iron 
8. TIBC 
9. Percentage saturation 
10. Ferritin 
 
Parameters Monitored during 
therapy  
Yes No 
1. Anaphylactic reaction  
(Hypotension) 
2. Nausea/vomiting 
3. Thrombo phlebitis 
4. Chills / rigors 
5. Joint pain 
6. Headache 
  
 
 
 
Post therapy assessment   
a) The following parameters assessed 1 month after therapy 
1. Hb 
2. Hematocrit 
3. Serum iron 
4. TIBC 
5. Percentage 
Saturation 
6. Ferritin  
  
b) The following parameters were assessed at delivery 
1) Hb 
2) Ferritin 
  
Details of delivery   
1. Delivery a) Term / Preterm 
b) Vaginal / Assisted 
vaginal / Caesarean 
section  
 
2. Complications 
during delivery  
If yes, specify 
3. Post delivery 
complication If yes, 
specify 
  
 
  
ABBREVIATIONS 
IV   Intravenous   
IM   Intramuscular 
Fe   Iron 
Hb   Hemoglobin  
PCV   Packed Volume  
TFR   Transferrrin Receptor 
rHuEPO  Recombinant Human Erythropoietin 
 BEFORE IRON SUCROSE AFTER 1 MONTH AT DELIVERY
S.No. NAME AGE OS MOD HB PCV 
SR. 
IRON TIBC 
% 
SAT PS S.FER HB PCV 
SR. 
IRON TIBC 
% 
SAT S.FER SE HB S.FER 
1 Egavalli 26 P2L2 6 7.5 21.5 63 395 15.9 MH 20 10.6 32 98 230 42.6 100 NO 11.5 215 
2 Vennila 20 P1L1 2 7.2 24 54 3.95 13.6 MH 15 9.5 26.5 80 340 23.5 94 NO 10.6 200 
3 Latha 19 P2L2 6 6.8 22 50 412 12.1 MH 13 9.0 28.2 83 345 24 90 NO 10.4 200 
4 Jothi 23 P1L1 2 8.0 25.5 64 400 16.0 MH 26 10.2 32 92 290 31.7 112 NO 11.0 223 
5 Thilaga 22 P2L2 2 7.4 22 60 380 15.7 MH 15 10.9 35 98 214 45.7 96 NO 11.2 205 
6 Vimala 24 P2L2 2 7.5 23 61 370 16.4 MH 22 11.0 36 94 220 42.7 105 NO 11.5 200 
7 Kala 25 P2L2 2 8.2 27 60 400 15.0 MH 30 11.5 37 96 290 33.1 110 NO 12.0 225 
8 Nagammal 30 P3L3 3 6.9 23 67 410 16.3 MH 13 9.6 30 100 270 37 95 NO 10.2 192 
9 Prema 20 P1L1 4 7.1 21 59 400 14.75 MH 16 9.5 29 90 296 30.4 92 NO 10.4 189 
10 Lalitha 24 P2L2 6 8.4 26 62 410 15.1 MH 27 10.1 32 105 230 45.6 97 NO 11.5 200 
11 Kavitha 23 P2L2 5 6.8 23 52 415 12.5 MH 13 9.2 28 85 215 39.5 86 NAU 10.1 164 
12 Jaya 18 P1L1 4 7.0 21 61 375 16.2 MH 16 10.5 33 98 215 45.5 98.5 NO 11.2 186.5 
13 Anitha 26 P1L1 2 8.3 27 64 352 18.1 MH 31 11.0 34 85 230 36.9 105 NO 12.0 205 
14 Jeyanthi 27 P2L2 3 7.5 24 62 380 16.3 MH 20 9.8 30 80 250 32 75 NO 10.5 150 
15 Devi 21 P2L2 2 7.2 23 58 400 14.5 MH 15 9.6 31 84 275 30.5 82 NO 10.2 170 
16 Jothi 22 P1L1 2 8.0 25.1 54 392 13.7 MH 28 11.0 34 87 270 32.2 94 NO 12.1 174 
17 Poongodi 19 P1L1 2 6.5 19 65 400 16.2 MH 12 8.5 24 88 290 30.3 72 NO 9.5 154 
 BEFORE IRON SUCROSE AFTER 1 MONTH AT DELIVERY
S.No. NAME AGE OS MOD HB PCV 
SR. 
IRON TIBC 
% 
SAT PS S.FER HB PCV 
SR. 
IRON TIBC 
% 
SAT S.FER SE HB S.FER 
18 Prabha 32 P2L2 3 9.2 28.5 76 325 23.3 MH 36 11.5 34 100 210 47.6 110 NO 13.0 215 
19 Uma 25 P2L2 6 8.5 26 60 390 15.3 MH 28 10.0 31 92 215 42.7 83 T 11.5 184 
20 Meena 27 P2L2 2 7.5 23 52 406 12.8 MH 22 9.8 30 88 275 32 75 NO 11.0 163 
21 Priya 27 P2L2 2 7.8 23 62 400 15.5 MH 21 10.1 32 96 295 32.5 82 NO 11.4 154 
22 Latha 23 P1L1 4 6.6 20.5 61 410 14.8 MH 13 9.0 28 90 290 31.03 69 NO 10.0 148 
23 Elizabeth 18 P1L1 2 8.2 25.5 64 380 16.8 MH 28 11.0 34 94 240 39.1 99 NO 12.2 187 
24 Ramya 29 P3L2 6 6.8 20.5 58 340 17.05 MH 12 9.6 29 89 220 40.4 56 H 10.5 110 
25 Vimala 23 P1L1 2 7.5 23 50 400 12.5 MH 25 9.8 29.5 85 285 29.8 96 NO 10.4 198 
26 Malathi 28 P1L1 2 9.3 28 70 320 21.8 MH 36 11.4 35 115 215 53.48 114 NO 12.5 210 
27 Sheela 20 P2L2 3 8.6 26 66 340 19.4 MH 29 10.5 32 88 210 41.9 94 NO 11.6 184 
28 Megala 30 P4L2 1 7.3 23 54 395 13.6 MH 17 9.8 29.5 92 250 36.8 84 NO 10.6 176 
29 Jaya 24 P1L1 2 8.0 25 58 410 14.1 MH 23 10.5 32 98 310 31.6 79 NO 11.7 180 
30 Sumathy 22 P1L1 4 7.2 22 62 385 16.1 MH 19 10.4 31.5 110 300 36.6 76 NO 11.6 168 
31 Nithya 27 P2L2 5 9.0 28 70 380 18.42 MH 28 11.2 34 115 200 57.5 88 NO 12.5 170 
32 Jothi 32 P3L2 1 7.4 23.5 54 400 13.5 MH 20 10.0 31.5 90 2800 32.1 74 NO 11.2 163 
33 Kaa 19 P1L1 4 8.2 25 64 350 18.2 MH 31 10.0 32 106 246 43.08 96 NO 11.6 202 
34 Nagammal 24 P1L1 2 6.8 20 65 425 15.2 MH 14 9.6 28.5 90 300 30 61 NO 10.0 110 
 BEFORE IRON SUCROSE AFTER 1 MONTH AT DELIVERY
S.No. NAME AGE OS MOD HB PCV 
SR. 
IRON TIBC 
% 
SAT PS S.FER HB PCV 
SR. 
IRON TIBC 
% 
SAT S.FER SE HB S.FER 
35 Indhira 28 P2L2 6 7.7 25 54 400 13.5 MH 19 10.1 32 87 290 30 70 NO 11.4 154 
36 Prabha 29 P2L2 6 9.4 30 72 325 22.1 MH 29 11.2 35 110 210 52.3 105 NO 12.0 196 
37 Poongodi 19 P1L1 2 7.2 21.5 56 410 13.6 MH 25 10.0 31.5 90 280 32.14 97 NO 11.3 174 
38 Meena 34 P3L3 1 6.9 22.5 64 410 15.3 MH 18 10.6 32.5 104 290 35.8 63 C 11.5 166 
39 Manimegalai 20 P1L1 4 7.3 23 60 390 15.38 MH 20 10.2 33.5 98 210 46.6 71 NO 11.5 153 
40 Faizana 26 P2L2 2 8.0 26 62 410 15.12 MH 29 11.0 35 105 295 35.5 85 NO 12.1 176 
41 Priya 26 P1L1 4 9.2 28.5 72 320 32.5 MH 33 11.5 35 115 200 57.5 85 NO 13.0 196 
42 Kamul Nisha 32 P3L3 1 6.8 21 56 410 13.6 MH 11 10.0 32 90 280 32.1 56 NO 11.4 107 
43 Jasmine 24 P1L1 2 7.0 22 58 400 14.5 MH 14 10.1 30.5 96 275 34.9 62 NO 11.5 142 
44 Mariam 27 P2L2 2 8.3 26.5 56 385 14.54 MH 23 10.8 35 98 255 38.4 73 NO 12.0 174 
45 Ponni 25 P1L1 4 7.8 24.5 54 390 13.8 MH 15 11.6 36 96 250 38.4 59 NO 12.5 140 
46 Geetha 20 P1L1 2 7.3 23.5 60 385 15.5 MH 13 10.5 32 85 250 34 64 NO 12.0 178 
47 Meena 23 P2L2 3 8.0 25.5 66 340 19.4 MH 22 11.0 34 97 215 45.1 92 C 13.5 200 
48 Rajeswari 26 P3L2 2 7.4 24 56 365 15.3 MH 17 10.0 31.5 83 245 33.8 67 NO 11.6 175 
49 Shanthi 30 P3L2 6 9.0 29 75 320 23.4 MH 31 11.5 33.5 110 225 48.8 98 NO 13.2 205 
50 Mary 24 P1L1 2 7.6 24 58 380 15.2 MH 17 10.2 31.5 87 235 37.02 65 NO 12.0 154 
 KEY TO MASTER CHART 
MOD   - Mode of Delivery 
1   - Labour Natural 
2   - Labour Natural with Episiotomy 
3   - Labour Natural with Lacerated Perineum 
4   - Emergency LSCS 
5   - Emergency repeat LSCS 
6   - Emergency repeat LSCS with Sterilisation  
OS   - Obstetric Score 
PS   - Peripheral Smear 
MH   - Microcytic Hypochromic picture 
% SAT  - Percentage Saturation  
S. FER  - Serum Ferritin 
TIBC   - Total Iron Binding Capacity 
SE   - Side Effects 
N   - No Side Effects 
NAU   - Nausea and Vomiting 
H   - Headache 
T   - Thrombophlebitis 
C   - Chills and Rigors 
